CALL/NOVO-NORDISK B/1350/0.1/16.01.26 | Real-time BOERSE MUENCHEN 13:27:06 05/06/2024 BST | ||
| 0.8 EUR | +1.27% |
|
| Current month | +2.60% | ||
| 1 month | +29.51% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 05/06/24 | 0.8 | +1.27% |
| 04/06/24 | 0.79 | +5.33% |
| 03/06/24 | 0.75 | -2.60% |
| 31/05/24 | 0.77 | +4.05% |
| 30/05/24 | 0.74 | +1.37% |
Real-time BOERSE MUENCHEN
Last update June 05, 2024 at 01:27 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Goldman Sachs |
| WKN | GG595S |
| ISIN | DE000GG595S8 |
| Date issued | 14/03/2024 |
| Strike | 1,350 kr |
| Maturity | 16/01/2026 (590 Days) |
| Parity | 10 : 1 |
| Emission price | 0.62 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.86 € |
|---|---|
| Lowest since issue | 0.58 € |
| Spread | 0.05 € |
| Spread % | 5.88% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
936.2
DKK
Average target price
920
DKK
Spread / Average Target
-1.73%
- Stock Market
- Warrants
- Warrant